Langasog, Fe L.

HRN: 18-87-84  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/07/2025
CEFTAZIDIME 1GM (VIAL)
06/07/2025
06/13/2025
IV
500 Mg
OD
Sepsis Sec To Infected Wound
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueCardiovascular    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: